1. Home
  2. XBIT vs MCRB Comparison

XBIT vs MCRB Comparison

Compare XBIT & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.35

Market Cap

74.4M

Sector

Health Care

ML Signal

HOLD

Logo Seres Therapeutics Inc.

MCRB

Seres Therapeutics Inc.

HOLD

Current Price

$6.49

Market Cap

71.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
MCRB
Founded
2005
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.4M
71.0M
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
XBIT
MCRB
Price
$2.35
$6.49
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.00
AVG Volume (30 Days)
26.1K
48.0K
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$789,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.09
$6.01
52 Week High
$3.61
$29.98

Technical Indicators

Market Signals
Indicator
XBIT
MCRB
Relative Strength Index (RSI) 39.19 33.70
Support Level $2.35 N/A
Resistance Level $2.41 $9.53
Average True Range (ATR) 0.06 0.66
MACD -0.01 -0.11
Stochastic Oscillator 13.79 22.01

Price Performance

Historical Comparison
XBIT
MCRB

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.

Share on Social Networks: